Deflazacort in Duchenne dystrophy: study of long-term effect

Area of Science:

• Neurology
• Pediatrics
• Clinical Pharmacology

Background:

• Duchenne muscular dystrophy (DMD) is a progressive genetic disorder causing severe muscle weakness.
• Current treatments for DMD offer limited efficacy in slowing disease progression.
• Identifying effective therapeutic interventions is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of deflazacort in patients with Duchenne muscular dystrophy.
• To assess the impact of deflazacort on motor function and ambulation.
• To compare the long-term effects of deflazacort versus placebo in DMD patients.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 28 DMD patients.
• Patients received either deflazacort (2.0 mg/kg alternate-day) or a placebo.
• Motor function assessments (stair climbing, chair rising, Gower's maneuver, walking, MRC index) and time to loss of ambulation were recorded over two years.

Main Results:

• Deflazacort treatment led to significant improvements in stair climbing, chair rising, Gower's maneuver, and walking after 6 months.
• These improvements were sustained at 1 and 2 years, with significant benefits in MRC index scores.
• The time to loss of ambulation was significantly longer in the deflazacort group (mean 33.2 months) compared to placebo (mean 20.5 months), with a median age of loss of ambulation of 11.8 years vs. 10.5 years.
• Mild side effects, including weight gain and behavioral changes, were observed.

Conclusions:

• Alternate-day deflazacort therapy demonstrates significant efficacy in improving motor function in Duchenne muscular dystrophy patients.
• Deflazacort treatment significantly delays the loss of ambulation in DMD patients.
• Deflazacort is a well-tolerated therapeutic option for managing Duchenne muscular dystrophy.